This document describes performance measures for heart failure that are appropriate for
public reporting or pay-for-performance programs and is meant to serve as a focused update …

Atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) and chronic kidney
disease (CKD) are major complications of type 2 diabetes (T2DM). The objectives of …

Introduction Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two
major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective …

Background and Aim: Dapagliflozin and empagliflozin have demonstrated favorable clinical
outcomes among patients with chronic kidney disease (CKD). However, their comparative …

Background The use of recommended heart failure (HF) medications has improved over
time, but opportunities for improvement persist among women and at rural hospitals …

Abstract Sodium-glucose cotransporter 2 (SGLT2) plays a pivotal role in mediating glucose
reabsorption within the renal filtrate, representing a well-known target in type 2 diabetes and …

Importance Cardiovascular disease (CVD) can be recurrent during type 2 diabetes (T2D)
progression in this aging population. The effectiveness of sodium-glucose cotransporter 2 …

Multiple large randomized clinical trials have confirmed sodium-glucose cotransporter-2
(SGLT2) inhibitors as highly efficacious therapy for patients with heart failure (HF) across the …

Abstract Purpose of Review Pharmacoequity refers to the goal of ensuring that all patients
have access to high-quality medications, regardless of their race, ethnicity, gender, or other …

Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular and
kidney benefits to patients with heart failure (HF) and/or chronic kidney disease (CKD) …